Mitsubishi UFJ Asset Management Co. Ltd. Raises Stock Position in Illumina, Inc. $ILMN

Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 12.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 138,171 shares of the life sciences company’s stock after purchasing an additional 15,456 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.09% of Illumina worth $13,183,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. raised its stake in shares of Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after acquiring an additional 99 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares during the period. Moors & Cabot Inc. grew its stake in shares of Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock valued at $465,000 after buying an additional 145 shares during the last quarter. Arkadios Wealth Advisors raised its holdings in shares of Illumina by 1.7% in the second quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock worth $871,000 after buying an additional 157 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of Illumina by 3.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock worth $445,000 after acquiring an additional 164 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 0.5%

Illumina stock opened at $121.98 on Thursday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The firm has a market cap of $18.64 billion, a P/E ratio of 15.44, a P/E/G ratio of 2.34 and a beta of 1.42. The business has a fifty day moving average of $101.96 and a two-hundred day moving average of $95.38. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business’s revenue was up .4% compared to the same quarter last year. During the same period last year, the business posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent analyst reports. Stephens set a $110.00 target price on Illumina and gave the stock an “overweight” rating in a research note on Monday, August 4th. Evercore ISI boosted their price objective on shares of Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Daiwa America lowered Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Robert W. Baird set a $109.00 target price on Illumina in a report on Friday, October 31st. Five equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus price target of $115.00.

Insider Buying and Selling

In other news, Director Scott Gottlieb purchased 500 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was acquired at an average cost of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares in the company, valued at $1,529,433.99. This represents a 4.16% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.60% of the company’s stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.